Mission Statement:

To improve the care and outcomes of kidney disease
patients worldwide through promoting coordination,
collaboration and integration of initiatives to develop
and implement clinical practice guidelines.

Home

Guidelines for Transplantation

Guideline Organization

Sub-topic

KDIGO

Care of Kidney Transplant Recipients

Published: Am J of Transplant (2009) 3 (Supple 9) S1-S155

  1. Induction Therapy
  2. Initial Maintenance Immunosuppressive Medications
  3. Long-Term Maintenance Immunosuppressive Medications
  4. Strategies to Reduce Drug Costs
  5. Monitoring Immunosuppressive Medications
  6. Treatment of Acute Rejection
  7. Treatment of Chronic Allograft Injury
  8. Monitoring Kidney Allograft Function
  9. Kidney Allograft Biopsy
  10. Recurrent Kidney Disease
  11. Preventing, Detecting, and Treating Nonadherence
  12. Vaccination
  13. Viral Diseases
  14. Other Infections
  15. Screening for New-Onset Diabetes after Transplantation
  16. Hypertension, Dyslipidemias, Tobacco Use, and Obesity
  17. Cardiovascular Disease Management
  18. Cancer of the Skin and Lip
  19. Non–Skin Malignancies
  20. Managing Cancer with Reduction of Immunosuppressive Medication
  21. Transplant Bone Disease
  22. Hematological Complications
  23. Hyperuricemia and Gout
  24. Growth and Development
  25. Sexual Function and Fertility
  26. Lifestyle
  27. Mental Health

CARI-Australia

CMV Disease and Kidney Transplantation (2004)

CMV Disease and Kidney Transplantation

Deceased Kidney Donor Suitability (2005)

Deceased Kidney Donor Suitability

Calcineurin Inhibitors in Renal Transplantation
(2007)

Calcineurin Inhibitors in Renal Transplantation

  • Adverse effects
  • IL2R as induction therapy
  • Nephrotoxicity and CNIs
  • Outcomes related to CNIs
  • Paediatric CNI Guidelines
  • Pregnancy and lactation
  • Therapeutic drug monitoring

Living Kidney Donors
(2007)

Draft - Under development

Living Kidney Donors

 

CSN-Canada

 

EBPG-Europe

European Best Practice Guidelines for Renal Transplantation

Part 1: 2000
  Sections I-III

Part 2: 2002
   Section IV

EVALUATION AND SELECTION OF DONORS

THE TRANSPLANT RECIPIENT FROM INITIAL TRANSPLANT HOSPITALIZATION TO 1 YEAR POST-TRANSPLANT

LONG-TERM MANAGEMENT OF THE TRANSPLANT RECIPIENT

KDOQI-US

Anemia in Chronic Kidney Disease (2006)

Bone Metabolism and Disease in Chronic Kidney Disease 2003

Bone Metabolism and Disease in Chronic Kidney Disease in Children 2005

Hypertension and Antihypertensive Agents in Chronic Kidney Disease 2006

UK-Renal Association

Module 4: Transplantation2007

Module 2: Complications
2007

Transplantation

Cardiovascular Disease: 1.9 Hypertension in renal transplant patients

National Institute for Health and Clinical Excellence (NICE) – United Kingdom